Heart HealthAntibody Cliramitug Clears Heart Amyloid Deposits Over 29 Months
Transthyretin amyloid cardiomyopathy (ATTR-CM) causes stiff, thickened hearts as misfolded protein deposits accumulate over time. Current treatments slow progression but do not remove existing amyloid. Cliramitug, a monoclonal antibody that targets misfolded transthyretin, was tested in an extended open-label follow-up involving 23 men with ATTR-CM, most on background tafamidis therapy. Over nearly 2.5 years, continued dosing and up-titration to 30 mg/kg reduced cardiac amyloid burden on MRI and bone scintigraphy, lowered heart-stress biomarkers NT-proBNP and troponin T, improved heart wall thickness and filling pressures, and raised patient quality-of-life scores. No serious treatment-related adverse events occurred. These findings suggest that actively clearing amyloid deposits — rather than just stabilizing the protein — may offer meaningful cardiac benefit.
